Novo Nordisk A/S Common Stock (NVO)

Viking's latest program seeks to push the envelope in weight loss efficacy.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Novo Nordisk is finally getting one up on its biggest rival.

All three can be bought on the dip.

Investors need to ask tough questions before initiating a position in this biotech company.

Don't wait until clinical milestones send their share prices soaring.

Eyes are on the rollout of Lilly's new weight loss pill.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

There are good reasons to invest in Lilly and to hold off.

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.

The stock has soared 400% in recent years.

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Don't sleep on these medical device leaders.

The stock is down, but it isn't out yet.

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Lilly offers investors safety and growth.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

The stock is known to soar on good news.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

These stocks are no-brainer buys.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.